SLC34A2 and lung carcinoma: In lung cancers, fusions with CD74 (83/216, 38.4%), EZR (28/216, 13.0%), SDC4 (26/216, 12.0%), and SLC34A2 (26/216, 12.0%) were highly frequent (Fig. 2c).